News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
866,973 Results
Type
Article (87756)
Company Profile (824)
Press Release (778377)
Multimedia
Podcasts (186)
Webinars (28)
Section
Business (233169)
Career Advice (4143)
Deals (39831)
Drug Delivery (144)
Drug Development (91357)
Employer Resources (203)
FDA (18357)
Job Trends (17414)
News (397706)
Policy (39947)
Tag
Academia (3006)
Academic (2)
Accelerated approval (25)
Adcomms (35)
Allergies (134)
Alliances (56980)
ALS (170)
Alzheimer's disease (1760)
Antibody-drug conjugate (ADC) (304)
Approvals (18463)
Artificial intelligence (578)
Autoimmune disease (134)
Automation (33)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (190)
Biotechnology (488)
Bladder cancer (150)
Brain cancer (61)
Breast cancer (620)
Cancer (4682)
Cardiovascular disease (408)
Career advice (3565)
Career pathing (40)
CAR-T (290)
CDC (59)
Celiac Disease (1)
Cell therapy (784)
Cervical cancer (36)
Clinical research (76545)
Collaboration (1597)
Company closure (5)
Compensation (1066)
Complete response letters (65)
COVID-19 (2978)
CRISPR (93)
C-suite (739)
Cystic fibrosis (147)
Data (5826)
Decentralized trials (2)
Denatured (68)
Depression (133)
Diabetes (494)
Diagnostics (7169)
Digital health (42)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (271)
Drug pricing (206)
Drug shortages (36)
Duchenne muscular dystrophy (224)
Earnings (99892)
Editorial (60)
Employer branding (25)
Employer resources (173)
Events (134510)
Executive appointments (1009)
FDA (21215)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (21)
Funding (1433)
Gene editing (202)
Generative AI (60)
Gene therapy (625)
GLP-1 (1082)
Government (5419)
Grass and pollen (8)
Guidances (379)
Healthcare (20941)
HIV (55)
Huntington's disease (45)
IgA nephropathy (80)
Immunology and inflammation (276)
Immuno-oncology (40)
Indications (76)
Infectious disease (3248)
Inflammatory bowel disease (197)
Inflation Reduction Act (16)
Influenza (111)
Intellectual property (217)
Interviews (816)
IPO (17942)
IRA (59)
Job creations (5198)
Job search strategy (2866)
Kidney cancer (17)
Labor market (88)
Layoffs (652)
Leadership (38)
Legal (10153)
Liver cancer (95)
Longevity (14)
Lung cancer (646)
Lymphoma (358)
Machine learning (40)
Management (66)
Manufacturing (748)
MASH (165)
Medical device (14970)
Medtech (15009)
Mergers & acquisitions (22875)
Metabolic disorders (1289)
Multiple sclerosis (152)
NASH (23)
Neurodegenerative disease (322)
Neuropsychiatric disorders (86)
Neuroscience (2958)
NextGen: Class of 2025 (7703)
Non-profit (5103)
Now hiring (61)
Obesity (619)
Opinion (326)
Ovarian cancer (153)
Pain (190)
Pancreatic cancer (200)
Parkinson's disease (272)
Partnered (34)
Patents (469)
Patient recruitment (403)
Peanut (58)
People (66630)
Pharmaceutical (145)
Pharmacy benefit managers (30)
Phase I (23632)
Phase II (33222)
Phase III (25046)
Pipeline (3878)
Policy (319)
Postmarket research (3554)
Preclinical (10665)
Press Release (72)
Prostate cancer (228)
Psychedelics (52)
Radiopharmaceuticals (287)
Rare diseases (805)
Real estate (7436)
Recruiting (80)
Regulatory (28563)
Reports (65)
Research institute (2715)
Resumes & cover letters (651)
Rett syndrome (24)
RNA editing (16)
RSV (82)
Schizophrenia (148)
Series A (235)
Series B (177)
Service/supplier (30)
Sickle cell disease (100)
Special edition (26)
Spinal muscular atrophy (174)
Sponsored (47)
Startups (4326)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (97)
The Weekly (116)
Vaccines (1106)
Venture capital (79)
Weight loss (433)
Women's health (79)
Worklife (21)
Date
Today (121)
Last 7 days (611)
Last 30 days (2618)
Last 365 days (33376)
2025 (32509)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1288)
Alabama (86)
Alaska (7)
Arizona (326)
Arkansas (14)
Asia (51312)
Australia (9017)
California (10813)
Canada (3169)
China (1051)
Colorado (455)
Connecticut (480)
Delaware (324)
Europe (117967)
Florida (1582)
Georgia (350)
Hawaii (3)
Idaho (68)
Illinois (890)
India (62)
Indiana (520)
Iowa (22)
Japan (376)
Kansas (130)
Kentucky (41)
Louisiana (28)
Maine (81)
Maryland (1395)
Massachusetts (8007)
Michigan (341)
Minnesota (625)
Mississippi (6)
Missouri (133)
Montana (34)
Nebraska (27)
Nevada (117)
New Hampshire (81)
New Jersey (2946)
New Mexico (32)
New York (2890)
North Carolina (1534)
North Dakota (10)
Northern California (5097)
Ohio (330)
Oklahoma (22)
Oregon (52)
Pennsylvania (2189)
Puerto Rico (20)
Rhode Island (48)
South America (1656)
South Carolina (60)
South Dakota (1)
Southern California (4152)
Tennessee (167)
Texas (1701)
United States (39320)
Utah (323)
Vermont (1)
Virginia (271)
Washington D.C. (85)
Washington State (915)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
There are 866,973 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Venture capital
Ambros Launches With $125M To Bring Italian Non-Opioid Pain Drug to America
Ambros Therapeutics’ non-opioid bisphosphonate analgesic, already approved in Italy, will soon begin a pivotal test in the U.S.
December 16, 2025
·
1 min read
·
Annalee Armstrong
FDA
J&J Wins Proactive FDA National Priority Voucher for Multiple Myeloma Combo
Johnson & Johnson, which did not apply for the national priority voucher, was granted the ticket based on results from a Phase III study testing Tecvayli plus Darzalex in patients with relapsed or refractory multiple myeloma.
December 16, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Zephyrus Innovations™ announces US FDA 510(k) clearance for VaporShield™ CSTD
December 16, 2025
·
2 min read
Press Releases
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth
December 16, 2025
·
2 min read
Press Releases
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)
December 16, 2025
·
3 min read
Press Releases
Calluna Pharma Announces the Appointment of Gijs van den Brink, MD, PhD, as Independent Director
December 16, 2025
·
2 min read
Press Releases
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
December 16, 2025
·
7 min read
Press Releases
Affibody Accelerates Phase 1 Study with ABY-271 Following Initial Patient Data
December 16, 2025
·
4 min read
Press Releases
Hamilton Launches GlucoSense, a First-of-Its-Kind, Real-Time, In Situ Glucose Sensor for Mammalian Cell Culture
December 16, 2025
·
5 min read
Press Releases
Genflow Completes Dosing Phase of Canine Gene Therapy Trial
December 16, 2025
·
6 min read
1 of 86,698
Next
